Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
2.9
Journals
JCM
Special Issues
Breast Cancer: Advances in Clinical and Personalized Practices
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Breast Cancer: Advances in Clinical and Personalized Practices

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: 25 March 2026 | Viewed by 2549

Special Issue Editors

Dr. Massimo Lodi

E-Mail Website
Guest Editor
1. Colmar Civil Hospitals, Colmar, France
2. Institute of Genetics and Molecular and Cellular Biology, Illkirch, France
Interests: breast cancer; breast surgery; breast reconstruction; artificial intelligence; oncological surgery
Dr. Sébastien Molière

E-Mail Website
Guest Editor
1. Strasbourg Univertsity Hospitals, Strasbourg, France
2. Institute of Genetics and Molecular and Cellular Biology, Illkirch, France
Interests: breast cancer; MRI; ultrasound; artificial intelligence; diagnostics

Special Issue Information

Dear Colleagues,

Breast cancer is a leading cause of cancer-related morbidity and mortality worldwide, and its impact will considerably grow in the future as the incidence is increasing. Despite significant progress in both diagnosis and treatment, challenges persist in managing this complex disease. This Special Issue aims to showcase the latest clinical advancements in breast cancer care while addressing critical issues that remain unresolved and require further research.

The scope of this Special Issue encompasses a variety of clinical topics, with a particular emphasis on imaging and diagnosis and on multimodal treatments, including oncological surgery and reconstruction, radiotherapy, and systemic treatments. We particularly welcome submissions focusing on multidisciplinary approaches and precision medicine strategies that are reshaping current clinical practice. Special attention will be given to studies exploring the integration of new technologies and their impact on patient outcomes. Finally, this Special Issue will cover quality of life and patient-centered outcomes.

We invite original research articles, clinical studies, systematic reviews, and meta-analyses from experts across all disciplines involved in breast cancer care. This includes medical oncology, radiation oncology, surgical oncology, radiology, pathology, and related specialties. By bringing together diverse perspectives from leading experts, this Special Issue aims to accelerate the translation of innovative research into clinical practice and ultimately improve outcomes for breast cancer patients.

Dr. Massimo Lodi
Dr. Sébastien Molière
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • radiology
  • surgical oncology
  • breast reconstruction
  • personalized medicine
  • quality of life
  • multidisci-plinary approach
  • new technologies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 728 KB  
Article
Neoadjuvant Chemotherapy for Early Breast Cancer: A Study on Response Rate and Toxicity
by Matt Galloway, Paula Barlow, Jody Jordan and Edward Lo
J. Clin. Med. 2025, 14(20), 7362; https://doi.org/10.3390/jcm14207362 - 17 Oct 2025
Viewed by 1022
Abstract
Background: Neoadjuvant chemotherapy (NACT) is widely used in patients with high-risk HER2-amplified (HER2+) or triple negative early breast cancer (TNBC). Advantages of NACT include allowing less extensive surgery, assessing response to treatment and guiding adjuvant therapy. NACT-related toxicities are common and can [...] Read more.
Background: Neoadjuvant chemotherapy (NACT) is widely used in patients with high-risk HER2-amplified (HER2+) or triple negative early breast cancer (TNBC). Advantages of NACT include allowing less extensive surgery, assessing response to treatment and guiding adjuvant therapy. NACT-related toxicities are common and can result in treatment alterations and hospitalisation, which may adversely impact outcomes. Aim: To assess NACT treatment in Hawke’s Bay (HB), New Zealand, by evaluating pathologic complete response (pCR) rates and toxicities of different regimens. Method: Data were retrospectively obtained from medical records of NACT patients. pCR rates were compared to results from the previous literature. Toxicity was assessed by recording severe (grade 3 or above) toxicities, treatment-limiting toxicities (those leading to dose reductions, dose delays or early cessation) and hospitalisations for different NACT regimens. Results: A total of 71 NACT patients were included. pCR rates for HER2+ disease and TNBC were 19/45 (42%) and 8/24 (33%), respectively. The most common severe toxicities were diarrhoea, anaemia and febrile neutropaenia (all 16%) in FEC-D (5-fluorouracil/epirubicin/cyclophosphamide + docetaxel +/− carboplatin +/− immunotherapy) patients, neutropaenia (50%) in FEC-DH (FEC-D + trastuzumab +/− pertuzumab) patients and diarrhoea (38%) in TCH (docetaxel/carboplatin/trastuzumab +/− pertuzumab) patients. Comparing treatment-limiting toxicity in FEC-DH vs. TCH, 9/16 (56%) vs. 13/21 (62%) had dose reduction, 2/16 (13%) vs. 8/21 (38%) had dose delay, 1/16 (6%) vs. 5/21(24%) had early cessation and 6/16 (38%) vs. 13/21 (62%) were hospitalised, respectively. Conclusions: NACT was associated with high rates of severe and treatment-limiting toxicity. Despite this, pCR rates were consistent with the previous literature. With the caveat of small patient numbers, FEC-DH-based therapy was associated with fewer dosing delays, early cessations and hospitalisations compared with TCH-based therapy. Full article
(This article belongs to the Special Issue Breast Cancer: Advances in Clinical and Personalized Practices)
►▼ Show Figures

Figure 1

14 pages, 1251 KB  
Article
Is There a Therapeutic Benefit of Axillary Surgery in Non-Metastatic Breast Cancer? A SEER Cohort Database Study
by Jonathan Sabah, Alexis Marouk, Sébastien Molière and Massimo Lodi
J. Clin. Med. 2025, 14(17), 6314; https://doi.org/10.3390/jcm14176314 - 6 Sep 2025
Viewed by 1059
Abstract
Background. Axillary lymph node biopsy (ALND) has traditionally been considered the gold standard for axillary staging and treatment in clinically node-positive breast cancer patients. However, in patients with nodal disease, the therapeutic benefit of ALND is uncertain. This study, based on a large [...] Read more.
Background. Axillary lymph node biopsy (ALND) has traditionally been considered the gold standard for axillary staging and treatment in clinically node-positive breast cancer patients. However, in patients with nodal disease, the therapeutic benefit of ALND is uncertain. This study, based on a large cohort, aims to evaluate breast cancer-specific survival depending on the extent of axillary surgery in non-metastatic breast cancer using real-world data from the Surveillance, Epidemiology, and End Results (SEER) database. Methods. This retrospective cohort study comprised 825,240 patients diagnosed with breast cancer between 2000 and 2020. Results. ALND was associated with a worse survival outcome in pN0 and pN1 populations (respectively, hazard ratio [HR] 1.16; 95% confidence interval [CI] 1.12–1.2; p < 0.001 and HR 1.38; 95%CI 1.3–1.46; p < 0.001). In pN2 and pN3 populations, there was ~4.3% relative reduction in the hazard of breast cancer-related death for each additional node removed; and higher positive-to-removed lymph node ratio was associated with worse prognosis (HR 3.450; 95%CI 2.99–3.98; p < 0.001). Conclusions. SLNB is associated with significantly better specific survival compared to ALND in negative/low axillary involvement, in higher axillary involvement categories extensive axillary surgery was associated with better prognosis. Full article
(This article belongs to the Special Issue Breast Cancer: Advances in Clinical and Personalized Practices)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop